Insecticides India Q3 FY26 Revenue Up 8% to ₹385 Cr Amid Headwinds
Insecticides (India) Limited reported Q3 FY26 revenue of ₹385 crore, an 8% increase year-on-year, driven by B2B segment growth. PAT declined 40% to ₹10 crore due to higher costs. Nine-month revenue grew 4% to ₹1,714 crore. The company launched five new products in 9MFY26.
The revenue growth is positive, but the substantial drop in PAT and margin compression due to industry headwinds indicate a mixed financial performance, impacting investor sentiment moderately.
While revenue saw growth, PAT declined significantly due to external headwinds and cost pressures. The company's outlook remains cautiously optimistic, acknowledging challenges while focusing on long-term strategies.
Insecticides (India) Limited (IIL) announced its financial results for the third quarter and nine months ended December 31, 2025. The company reported a consolidated revenue from operations of ₹385 crore for Q3 FY26, an 8% increase compared to ₹358 crore in Q3 FY25. For the nine months ended December 31, 2025 (9MFY26), revenue grew by 4% to ₹1,714 crore from ₹1,641 crore in the same period last year.
The revenue growth in Q3 was primarily driven by a robust performance in the B2B segment. However, B2C sales were impacted by macro industry headwinds, including erratic rainfall and a muted spraying season. Gross profit for Q3 FY26 moderated by 3% to ₹125 crore from ₹129 crore in Q3 FY25, with gross profit margins at 32.4% compared to 36.1% in the previous year. EBITDA decreased by 11% to ₹27 crore in Q3 FY26 from ₹31 crore in Q3 FY25. Profit After Tax (PAT) saw a significant decline of 40% to ₹10 crore in Q3 FY26, down from ₹17 crore in Q3 FY25, impacted by increased finance costs and depreciation.
During 9MFY26, the company launched a total of five new products, strengthening its pipeline. IIL also conducted aggressive demand generation initiatives, including over 25,000 farmer meetings and 5,000 field days. New product launches such as Sparcle, Centran, and Torry Super witnessed encouraging farmer adoption. Commenting on the results, Mr. Rajesh Kumar Aggarwal, MD of Insecticides (India) Ltd., stated that the company delivered a resilient performance despite challenging operating conditions and expects margin compression to be transitory. He highlighted the continued investment in brand building and farmer engagement.
What to do with a filing like this
Insecticides (India) Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Insecticides (India) Limited. Read the original for the full detail.